"Detailed Results of Phase  Trial Presented at the American College of Gastroenterology  Annual Scientific Meeting   . of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good Compared to . of Those Using Standard Prep Products in Colonoscopistblinded Trial   Phase  Study Planned to Initiate in Early    More Patientfriendly Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening Newton MA October    Detailed results from a Phase  study of a novel colonoscopy prep ECP under development by ColonaryConcepts LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations while offering a much higher level of patient satisfaction and preference than standard preps. The investigational prep is designed to be goodtasting with no fasting and lower fluid requirements than standard preps. It consists of nutritionally balanced bars and beverages incorporating the standard purgative active ingredient PEG  which a patient consumes during the  hours prior to colonoscopy. Results from the randomized singleblind study will be presented today at the American College of Gastroenterology  Annual Scientific Meeting being held in Las Vegas NV by principal investigator Douglas K. Rex M.D. Distinguished Professor of Medicine Indiana University School of Medicine. Approximately  of those who ought to have a colonoscopy avoid the procedure and the top reason cited for their avoidance is the prep said Dr. Rex. Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations. Moreover the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially lifesaving colorectal cancer screening procedure. The study tested six formulations of ECP using different doses of the active ingredients integrated within different meal kit menus randomized against two U.S. Food and Drug Administrationapproved active comparators. The primary outcome was the proportion of subjects with an endoscopic visibility rating of excellent or good based on the Aronchick scale. Secondary endpoints included segmentbysegment endoscopic visibility based on the Ottawa scale as well as safety tolerability and reports of patient experience. Fiftyone patients were treated with ECP and  with active comparators.  In the top three most effective formulations of ECP .  of  of patients had a rating of excellent or good. With ColonaryConcepts lead formulation .  of  of patients had a rating of excellent or good with  of  colon segments rated as excellent or good on the Ottawa scale. For the comparator products .  of  had a rating of excellent or good. There were no serious adverse events across any of the treatment groups. The proportion of patients reporting being satisfied or extremely satisfied with the experience of using the lead ECP formulation was nearly double that for those using the standard preps . versus .. We are very pleased with the efficacy and safety results of this study which clearly support advancing this product to a Phase  trial said Corey A. Siegel M.D. M.S. a cofounder of ColonaryConcepts and Director of the Inflammatory Bowel Disease Center at the DartmouthHitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth. The ECP approach allows patients to eat solid food bars and drink palatable lowvolume beverages a patientfriendly design that participants in the study clearly favored over conventional preps comments Dr. Siegel. Patients participating in the study were nearly four times more likely to recommend ECP to their friends and family as compared to the standard colonoscopy prep.  Colonoscopy is still recognized as the gold standard  the best way to catch this cancer at an early stage. The medical community has called for an increase in colorectal cancer screening overall both through the recent recommendations of the Cancer Moonshot Blue Ribbon Panel and the National Colorectal Cancer Roundtables call for  screening by  said Joshua Korzenik M.D. a cofounder of ColonaryConcepts and Faculty Member at Harvard Medical School and the Director of the Brigham and Womens Hospital Crohns and Colitis Center. By making the preparation for the procedure easier we believe ECP can lower patient resistance to colonoscopies and thus can help attain these important public health goals.   About ColonaryConcepts LLC  ColonaryConcepts LLC is headquartered in Newton MA and is committed to developing patientcentric innovations that improve gastrointestinal health. The company currently has two product candidates in clinical development ECP which is expected to enter Phase  clinical trials in early  and the Cbar a novel product candidate for chronic constipation which is currently being studied in a Phase b clinical trial. ColonaryConcepts physicianled product development team includes Boardcertified gastroenterologists food scientists pharmaceutical development experts culinary research chefs and product design strategists. For more information about ColonaryConcepts LLC please visit http Media Contact Joan E. Kureczka  Bioscribe Inc.  Email Joanbioscribe.com mailtoJoanbioscribe.com  Ph .. ColonaryConcepts Michael Allio  ..  michael.alliogmail.com mailtomichael.alliogmail.com Herb Stern  ..  infocolonaryconcepts.com mailtoinfocolonaryconcepts.com"